What is VitriVax?
VitriVax is a specialized biotechnology enterprise dedicated to the development of thermostable, single-dose vaccines. By leveraging its innovative ALTA technology, the company aims to eliminate the cold-chain requirements that currently hinder vaccine distribution in resource-limited settings. This technological advancement is designed to enhance both the efficacy and the accessibility of life-saving immunizations, addressing significant public health challenges on a global scale. By focusing on the stability of biological products, VitriVax is effectively bridging the gap between laboratory innovation and real-world clinical application.
How much funding has VitriVax raised?
VitriVax has raised a total of $22.3M across 2 funding rounds:
Grant
$5M
Series B
$17.3M
Grant (2023): $5M with participation from Bill & Melinda Gates Foundation
Series B (2025): $17.3M led by RA Capital Management and Adjuvant Capital
Key Investors in VitriVax
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their TechAtlas think tank to drive strategic decisions.
Adjuvant Capital
A venture capital firm dedicated to financing life science technologies that address high-burden public health challenges, with a specific focus on infectious diseases and underserved populations.
Bill & Melinda Gates Foundation
A philanthropic organization focused on supporting individuals experiencing hunger and extreme poverty, with a long-standing commitment to improving global health outcomes through medical innovation.
What's next for VitriVax?
With the recent influx of capital, VitriVax is well-positioned to accelerate its clinical development programs and scale its manufacturing capabilities. The strategic focus will likely shift toward regulatory milestones and the expansion of its pipeline to include a broader range of infectious disease targets. As the company moves deeper into its Series B lifecycle, the emphasis will remain on validating the ALTA platform's performance in diverse environmental conditions, thereby securing its competitive advantage in the global health market. Future growth will be defined by the successful transition of its lead candidates through late-stage clinical trials and the establishment of strategic partnerships to facilitate large-scale distribution.
See full VitriVax company page
